Last reviewed · How we verify
fampridine
At a glance
| Generic name | fampridine |
|---|---|
| Also known as | dalfampridine, Ampyra, Fampyra, fampridine prolonged-release tablets, BIIB041 |
| Sponsor | Biogen |
| Target | Voltage-gated potassium channel, Potassium voltage-gated channel subfamily C member 1, Potassium voltage-gated channel subfamily C member 2 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| Annual revenue | 400 |
Approved indications
- Multiple sclerosis
Common side effects
Key clinical trials
- Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor (PHASE1)
- 4-Aminopyridine to Treat Skin Burns (PHASE2)
- Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis (PHASE4)
- 4AP for Carpal Tunnel Syndrome (CTS) (PHASE2)
- 4-aminopyridine Treatment for Nerve Injury (PHASE2, PHASE3)
- Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression (PHASE2)
- A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene (PHASE3)
- Firdapse for Post-BOTOX Vocal Weakness (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fampridine CI brief — competitive landscape report
- fampridine updates RSS · CI watch RSS
- Biogen portfolio CI